Introduction
IFN-␣ therapy is applied for the clinical treatment of multiple sclerosis, several malignancies such as renal carcinoma, melanoma, and hairy cell leukemia as well as viral infections including hepatitis B and C. However, its application is limited primarily by the toxicity associated with systemic delivery. Gene therapy approaches have been developed allowing paracrine cytokine delivery by genetically modified cells delivered into the microenvironment of tumors, thereby reducing systemic circulation of the cytokine. This creates a local inflammatory response associated with recruitment and activation of immune cells. 1, 2 In murine models, several studies with genetically modified tumor cells producing IFN-␣ have been previously reported, and the efficiency of IFN-␣ transduction for reducing tumorigenicity has been demonstrated. [3] [4] [5] [6] Rejection of IFN-␣-transduced tumor cells depends on a CD8
+ cell-mediated immune response.
mediating the antitumor immune responses. 7 Antigenspecific activation of T lymphocytes is mediated by T cell receptor (TCR) ligation by peptide-major histocompatibility complexes (MHC) as well as secondary signals through costimulatory molecules such as CD80 or CD86 (B7.1 or B7.2).
8 CD80 and CD86 bind to CD28 on T cells, induce serine/threonine phosphorylation of CD28, 9 and transduce signals important for T cell clonal expansion. [10] [11] [12] [13] The CD80/86-CD28 interaction is a necessary and sufficient costimulant for CD8 + CTL generation in the absence of exogenous help, 14 and interaction between antigen-MHC complex and the TCR without costimulation may lead to T cell clonal anergy or apoptosis. 15 Inoculation of tumor cells transduced with CD80 enhances the induction of antitumor immunity. 16, 17 Immunogenic tumors, in particular, regress completely when transduced with CD80. 18 We have demonstrated that co-expression of IL-12 and CD80 promotes tumor regression in therapeutic models. 19 In this study, we examined whether IFN-␣ and CD80 transduction of tumor cells would also display synergistic effects on the induction of antitumor immunity in the setting of an established tumor.
Results
Successful production of IFN-␣ and expression of CD80 following retroviral transduction of MC38 and MCA205 tumor cells MC38 and MCA205 tumor cell lines were stably transduced with retroviral vectors encoding murine IFN-␣2, murine CD80, or the neomycin-resistance (Neo) gene as described in Materials and methods. Production of IFN-␣ was confirmed by ELISA. IFN-␣-transduced MC38 (MC38-IFN␣) and MCA205 (MCA205-IFN␣) tumor cells secreted 80 ng (2400 U)/10 6 cells/48 h and 100 ng (3000 U)/10 6 cells/48 h of IFN-␣, respectively ( Figure 1a ). Figure 2a .
Figure 1 IFN-␣ or CD80 transduction of tumor cells does not
Similar results were observed in the MCA205 tumor model, where IFN-␣ transduction also led to a significant reduction of in vivo tumor growth (P = 0.034 on day 21). A total of seven of 15 mice inoculated with MCA205-IFN␣ remained tumor-free for 50 days and six of seven mice rejected a subsequent tumor rechallenge with 3 × 10 5 wild-type tumor cells. While MCA205-CD80 grew somewhat slower than MCA205-WT or MCA205-Neo, all mice had to be eventually killed due to their tumor burden. A representative experiment with five mice per group is shown in Figure 2b . This antitumor effect appears to be dose dependent, since another MCA205-IFN␣ tumor cell line which only produced 12 ng (360 U)/10 6 cells/48 h of IFN-␣ grew slowly but progressively after inoculation and eventually led to the demise of all animals (data not shown). Figure 3b . Taken together, these results demonstrate enhanced antitumor effects of IFN-␣ and CD80 transduction on inhibiting tumor establishment in two poorly immunogenic tumor models.
Repetitive therapeutic inoculations with IFN-␣-transduced MC38 tumor cells suppresses the in vivo growth of established MC38 tumors on the contralateral flank We examined the therapeutic effects of immunizations using tumor cells genetically modified to express IFN-␣ or CD80 in the MC38 tumor model. Mice bearing established wild-type MC38 tumors were treated by injection of these tumor cells in the contralateral flank starting on day 10. No effect on tumor growth was observed when MC38-IFN␣ cells were injected only once. Starting 10 days after inoculation of MC38-WT, mice were injected every 3 days with MC38-IFN␣ tumor cells in the opposite flank. Repetitive immunizations with MC38-IFN␣ alone or in combination with MC38-CD80 significantly suppressed outgrowth of the established MC38 tumor when compared with mice immunized with MC38-Neo (P = 0.0094 or P = 0.0034, respectively). A representative experiment with five mice per group is shown in Figure  4 . In these experiments, all mice bearing an established tumor eventually had to be killed because of progressive tumor growth. 
Figure 3 IFN-␣ and CD80 transduction combination effectively prevents tumor establishment. Combinations of (a) MC38-Neo, MC38-CD80 and MC38-IFN␣, or (b) MCA205-Neo

Cytolytic response specific for MC38 is induced from MC38-immune mice
To demonstrate the systemic induction of specific cytolytic response against MC38 in the MC38-IFN␣-immunized mice, we stimulated splenocytes from these mice with MC38-CD80 cells every week in vitro. Cytolytic activity against MC38-WT was detected in over 30% of tumor cells in a 4-h 51 Cr release assay at an effector to target ratio of 40:1 after second stimulation, and increased to 78.5% after the fourth stimulation. Significant cytotoxicity against YAC-1 was not observed at any time ( Figure 6 ). These results suggested that systemic cellular antitumor response was induced by injection with MC38-IFN␣ cells.
Discussion
We demonstrated the efficacy of IFN-␣ gene therapy alone or in combination with CD80 gene transduction in two poorly immunogenic murine tumor models. Furthermore, we demonstrated that established poorly immunogenic tumors can be treated by repetitive immunizations with IFN-␣-and CD80-expressing tumor cells on the contralateral flank. Immunohistochemical studies revealed infiltration of the treated tumor with CD4
+ and CD8
+ T cells as well as NLDC-145
+ DCs in association with this therapy, suggesting that IFN-␣ and CD80 gene therapy can effectively stimulate cellular antitumor immunity. They support our observation that potent cytotoxic T lymphocytes (CTLs) specific for MC38 can be obtained from MC38-IFN-␣-immunized mice using in vitro stimulation with CD80-transduced MC38. We also found that IFN-␣ and CD80-transduced MC38 cells enhance the pro- liferation of an MC38-specific CTL line, most likely by preventing apoptosis following restimulation with MC38 tumor cells. 20 Our observations are consistent with a recent report showing that IFN-␣ (as well as IFN-␤ and the ␥c chain of receptor utilizing cytokines, IL-2, IL-4, IL-7 and IL-15) can directly counteract T cell apoptosis following antigen-specific stimulation. 21 IFN-␣ has been widely applied in the treatment of a number of malignancies. Nevertheless, it is still not exactly clear how it exerts its potent antitumor effects. IFN-␣ is produced by a subset of cells in human peripheral blood in response to various viruses and bacteria and has a variety of biological functions. IFN-␣ not only inhibits viral replication and cellular proliferation but also acts as a mediator of innate and adaptive immunity. DC can produce IFN-␣ 22 and it has recently been demonstrated that IFN-␣ promotes the maturation of DC. 23 DC are also critical for the induction of cellular antitumor immunity in animal tumor models. 24, 25 They are specialized for tumor antigen capture in peripheral tissue and can migrate to secondary lymphoid organs in response to inflammatory signals. Migrating DC process antigens and up-regulate surface expression of MHC molecules and constimulatory molecules such as CD80 and CD86. Upon arrival in lymphoid organs they specifically interact with and stimulate naive antigen-specific T lymphocytes. DC can produce immunostimulatory cytokines such as IFN-␣ or IL-12, which play important roles in T cell differentiation towards a type 1 helper T cell (Th1) response associated with cellular immunity. [26] [27] [28] [29] [30] Furthermore, like IL-12, IFN-␣ has been shown to mediate antiangiogenic effects in murine and human tumors.
Based on our findings, we hypothesize that paracrine delivery of IFN-␣ within the tumor microenvironment causes an inflammatory reaction capable of enhancing the function of DC as well as T lymphocytes, and promotes a Th1-biased immune response with a strong cytotoxic T cell component. The additional expression of CD80 synergizes with IFN-␣ in the induction and maintenance of cellular immune responses by providing secondary constimulatory signals which counteract T cell apoptosis at the site of tumor inoculation. This therapy, unlike systemic delivery, is associated with no apparent toxicity and may provide similar benefits without the morbidity associated with systemic delivery. These results warrant further preclinical investigations of IFN-␣ and CD80 gene therapy. We are now exploring the appropriate means to deliver the cytokine (and costimulatory molecule) including ex vivo transfection of fibroblasts or DC with retroviral vectors or in vivo application of adenoviral vector.
Materials and methods
Mice
Female B6 mice, 6-to 8-weeks-old, were purchased from Taconic Farms (Germantown, NY, USA) and used in experiments when they were 8-to 12-weeks-old. Animals were maintained in a specific pathogen-free facility (Central Animal Facility, University of Pittsburgh, PA, USA).
Cell lines and culture medium
The murine colorectal adenocarcinoma cell line MC38, 31 the methylcholanthrene-induced fibrosarcoma cell line MCA205 (both of B6 mice origin), and YAC-1 lymphoma cells, used as target cells for detecting non-specific killing in cytolytic assays, were kindly provided by Dr SA Rosenberg (Surgery Branch, National Cancer Institute, Bethesda, MD, USA). Cells were maintained in RPMI 1640 supplemented with 10% heat-inactivated FCS, 2 mm l-glutamine, 100 IU/ml penicillin, 100 g/ml streptomycin, 10 mm Hepes buffer, 1 mm MEM sodium pyruvate, 0.1 mm MEM non-essential amino acids (complete medium) in a humidified incubator with 5% CO 2 in air at 37°C. Cells were determined to be free of mycoplasma contamination (detected by Mycoplasma T C; GeneProbe, San Diego, CA, USA). All cell culture reagents were purchased from Life Technologies (Gaithersburg, MD, USA).
Antibodies and reagents
Flow cytometry was performed using FACScan (Becton Dickinson, San Jose, CA, USA); antibodies to CD80 or K b were obtained from Becton Dickinson.
Retroviral construct and genetically modified tumor cell lines A producer cell line for the retroviral vector, SAM-B7.1-EN 32 was kindly provided by Dr P Hwu (National Cancer Institute). The construction and characterization of the DFG-murine IFN-␣2-neo retroviral vector has been described previously. 33 Tumor cells were retrovirally transduced using standard protocols 34 and selected for antibiotic resistance in culture medium containing 0.75 mg/ml, G418 (Life Technologies). The expression of murine CD80 on the surface of transduced tumor cells was confirmed by flow cytometry using a monoclonal antibody specific for murine CD80, and the expression of murine IFN-␣2 was confirmed by ELISA. Tumor cells expressing the neomycin-resistance gene following retroviral transduction with MFG-Neo were kindly provided by Dr T Iwazawa (University of Pittsburgh).
Determination of in vitro growth of wild-type and genetically modified tumor cells 2 × 10 5 wild type, Neo-, murine CD80-, or murine IFN-␣2-transduced MC38 or MCA205 cells were incubated in six-well plates with complete medium. A total of nine wells were prepared for each tumor cell line. Three wells were harvested and each the number of cells per well was counted under microscopy every 3 days. 
Tumor models
Immunohistologic analysis
Tumor tissues were harvested 3 days after inoculation of genetically modified tumor (13 days after wild-type inoculation), and were immediately embedded in OCT compound (Miles, Elkhart, IN, USA) and frozen. Serial 5-m sections were stained using antibodies to CD4, CD8␣ (obtained from Pharmingen, San Diego, CA, USA), or NLDC-145 (obtained from Serotec, Oxford, UK). Rat IgG2a (obtained from Pharmingen) was used as control antibody. The Vectastain ABC kit (Vector, Burlingame, CA, USA) and AEC were used for development.
Induction of tumor-specific CTL MC38-immune mice were generated by initial injection with 1 × 10 5 non-irradiated MC38-IFN␣ on day 0. Subsequently, tumor-free animals rejected a challenge with 3 × 10 5 MC38-WT on day 35. Splenocytes (3 × 10 6 cells/ml) from these immune mice were harvested on day 49 and stimulated with irradiated (100 cGy) MC38-CD80 tumor cells (3 × 10 5 cells/ml). Seven days later, responder cells (1 × 10 6 cells/ml) were restimulated with irradiated MC38-CD80 tumor cells (1 × 10 5 cells/ml), syngeneic naive splenocytes (1 × 10 6 cells/ml), and 50 IU/ml of recombinant human IL-2 (Chiron, Emoryville, CA, USA). These responder cells were stimulated weekly, and cytolytic assays were performed 5 days after the last stimulation using the responder cells as effector cells. 51 Cr release was measured after a 4-h incubation at 37°C. Percentage lysis was determined using the following formula: (release in assay − spontaneous release) × 100/(maximum release − spontaneous release). Maximum release was determined by lysis of labeled target cells with 1% Triton X-100. Spontaneous release was measured by incubating target cells in the absence of effector cells and was less than 15% of maximum release.
Statistical analyses
Significance was assessed by Student's t test. The difference between groups was considered statistically significant when the P value was lower than 0.05.
